These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33772436)

  • 1. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
    Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
    Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
    Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
    MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling.
    Rossotti MA; Henry KA; van Faassen H; Tanha J; Callaghan D; Hussack G; Arbabi-Ghahroudi M; MacKenzie CR
    Biochem J; 2019 Jan; 476(1):39-50. PubMed ID: 30455372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer.
    Ashton JR; Gottlin EB; Patz EF; West JL; Badea CT
    PLoS One; 2018; 13(11):e0206950. PubMed ID: 30408128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation.
    Li L; Zhu Y; Liu M; Jin D; Zhang L; Cheng J; Liu Y
    J Inorg Biochem; 2021 Oct; 223():111553. PubMed ID: 34340059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
    Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
    Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
    Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
    Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
    Tijink BM; Laeremans T; Budde M; Stigter-van Walsum M; Dreier T; de Haard HJ; Leemans CR; van Dongen GA
    Mol Cancer Ther; 2008 Aug; 7(8):2288-97. PubMed ID: 18723476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
    Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
    Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.